Last reviewed · How we verify
Opioid stable treatment
Opioid stable treatment is a Opioid agonist maintenance therapy Small molecule drug developed by Rigshospitalet, Denmark. It is currently in Phase 3 development for Opioid use disorder maintenance treatment, Prevention of opioid withdrawal and relapse.
Opioid stable treatment maintains consistent opioid dosing to prevent withdrawal and reduce illicit drug use in opioid-dependent patients.
Opioid stable treatment maintains consistent opioid dosing to prevent withdrawal and reduce illicit drug use in opioid-dependent patients. Used for Opioid use disorder maintenance treatment, Prevention of opioid withdrawal and relapse.
At a glance
| Generic name | Opioid stable treatment |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Opioid agonist maintenance therapy |
| Target | Mu opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Substance Use Disorder |
| Phase | Phase 3 |
Mechanism of action
This is a maintenance therapy approach that provides stable, regulated opioid dosing (typically methadone or buprenorphine) to opioid-dependent individuals. By maintaining consistent blood levels of opioid agonists, the treatment prevents withdrawal symptoms, reduces cravings, and decreases the reinforcing effects of additional illicit opioid use, thereby supporting addiction recovery and harm reduction.
Approved indications
- Opioid use disorder maintenance treatment
- Prevention of opioid withdrawal and relapse
Common side effects
- Constipation
- Sedation
- Respiratory depression
- Overdose risk
Key clinical trials
- A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy (PHASE4)
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Anesthesia sTrategy foR Organ Procurement In braiN dEath (PHASE3)
- Slow Opioid Tapering Pilot Study of Patients Using Chronic Opioid Therapy (NA)
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (PHASE3)
- Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (PHASE3)
- Integrating Brain, Neurocognitive, and Computational Tools in OUD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Opioid stable treatment CI brief — competitive landscape report
- Opioid stable treatment updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI
Frequently asked questions about Opioid stable treatment
What is Opioid stable treatment?
How does Opioid stable treatment work?
What is Opioid stable treatment used for?
Who makes Opioid stable treatment?
What drug class is Opioid stable treatment in?
What development phase is Opioid stable treatment in?
What are the side effects of Opioid stable treatment?
What does Opioid stable treatment target?
Related
- Drug class: All Opioid agonist maintenance therapy drugs
- Target: All drugs targeting Mu opioid receptor
- Manufacturer: Rigshospitalet, Denmark — full pipeline
- Therapeutic area: All drugs in Addiction Medicine / Substance Use Disorder
- Indication: Drugs for Opioid use disorder maintenance treatment
- Indication: Drugs for Prevention of opioid withdrawal and relapse
- Compare: Opioid stable treatment vs similar drugs
- Pricing: Opioid stable treatment cost, discount & access